Rubedo.Life
Featured Project

Rubedo.Life

Ageing
Respiratory Disease
Dermatology
Rubedo is building a platform for longevity medicines using “smart drugs” (prodrugs) that have the capacity to selectively be activated in target cells predicted to be pathogenic and the cause of age-related diseases.
Licensing Outreach
Investment
$ 350,000
Initiated
14.12.2021
Approval
100% Voted Yes
Project Details
Marco Quarta
Co-founder and CEO
Mark Gallop
Co-founder
Alex Laslavic
CTO
AT A GLANCE
Stage
Series A, Pre-clinical - lead optimisation
Area
Drug discovery platform
Status
Ongoing
Patent
Patents acquired
PROJECT LINKS
Rubedo Website

Background

Rubedo has started developing therapeutics for idiopathic pulmonary fibrosis (IPF) and lung cancer. IPF is an orphan disease, with a potentially accelerated clearance by the FDA. They work with published and proprietary databases that they have generated in-house.

Rubedo’s proprietary ALEMBIC™ drug discovery platform is based on a synergy between sophisticated computational and chemistry strategies.

This hybrid platform enables the discovery and development of novel first-in-class engineered small molecules, such as prodrugs, designed to selectively target certain types of “bad” cells, like senescent cells, which play a key role in the progression of chronic disorders.

Aims, Hypothesis & Results

The team has identified a portfolio of small molecules that target signature metabolism features of rare (presumably pathogenic) cells and are currently working to test and optimize these compounds in preclinical models.

Timeline

Pre-Clinical Studies: Lead Optimisation for 4 drugs in the pipeline

VitaDAO Board Evaluation Writeup

This platform has a high potential for impact since it can be applied to a wide variety of cellular phenomena ranging from eliminating pathogenic cells, regenerating stem cells, removing ECM debris, repairing mitochondria, etc.Focusing on prodrugs is a valuable approach since it allows for the delivery of drugs to be highly cell-specific and avoid off-target effects.


Their successful proof-of-concept for targeting cellular senescence is a great example of this and shows strong in vivo results with virtually no off-target effectsHowever, it has yet to be seen if they will be as successful in targeting other cellular phenomena as they are with cellular senescence. Also, it is still unclear how these prodrugs will be delivered in vivo and what their plan is to address this, but I don’t see this as a major hindrance to the company’s success at this stage. Overall, Rubedo’s workflow is logical and feasible - from target discovery in silico, moving to in vitro testing, and finally in vivo - and the ALEMBIC platform is very promising for the longevity field, and possibly other fields as well

Latest Project Updates
No items found.
14
December
2021
Project Initiated!

Discover more projects & initiatives

Scheibye-Knudsen Lab
What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.
Support of Clinical Trial - The Effect of Regular Exercise & Intermittent Rapamycin Dosing
This clinical trial aims to investigate whether periods of time where the mechanistic target of Rapamycin (mTOR) pathway is activated via exercise, combined with alternate periods of time where mTOR is inhibited using Sirolimus (Rapamycin), will result in greater muscle performance in older adults compared with just exercise alone.

About VitaDAO

Who can apply?
What types of projects do you fund?
What is the application structure?
Who owns IP from funded projects?
What project stages do you fund?